Patient Preferences for Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHY) in Adults with Primary Immunodeficiencies (PI): Phase 3 Study Results

被引：0
|
作者：
Ito, D. [1 ]
Ye, X. [2 ]
Xiong, Y. [1 ]
Li-McLeod, J. [1 ]
Schiff, R. [1 ]
Faivre, P. [3 ]
机构：
[1] Baxter HealthCare, Med Outcomes Res & Econ, Westlake Village, CA USA
[2] Baxter HealthCare, Med Outcomes Res & Econ, Deerfield, IL USA
[3] Baxter HealthCare, Hlth Econ & Market Access, Westlake Village, Switzerland
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
ESID-0294
引用
收藏
页码：S381 / S382
页数：2
相关论文
共 46 条
  • [41] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark
    Kobrynski, Lisa
    Gupta, Sudhir
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S54
  • [42] Safety, Tolerability and Pharmacokinetics (PK) of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Interim Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiencies (PI)
    Krivan, Gergely
    Borte, Michael
    Marodi, Laszlo
    Derfalvi, Beata
    Dicso, Ferenc
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Schiff, Richard I.
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 384 - 384
  • [43] A NOVEL IGSC TREATMENT: DESIGN OF A PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
    Sommer, C. L.
    England, J.
    Jakobsen, J.
    Reeve, R.
    Gelmont, D.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 212 - 212
  • [44] SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS (IGSC), 20 %: INTERIM ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
    Krivan, Gergely
    Borte, Michael
    Gulacsy, Vera
    Harrer, Thomas
    Ganschow, Rainer
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (03) : 698 - 698
  • [45] Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study
    Weller, K.
    Maurer, M.
    Magerl, M.
    Fridman, M.
    Supina, D.
    Schranz, J.
    ALLERGY, 2015, 70 : 253 - 253
  • [46] Immune globulin subcutaneous, human - klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study
    Sleasman, John
    Lumry, William
    Hussain, Iftikhar
    Wedner, H. James
    Harris, James
    Mondou, Elsa
    Lin, Jiang
    Hames, Carrie
    Querolt, Montse
    Stein, Mark
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB71 - AB71
12345